|SPECIAL ARTICLE (GUIDELINES)
|Year : 2019 | Volume
| Issue : 4 | Page : 30-36
The Indian Society for Study of Pain, Cancer Pain Special Interest Group guidelines on pharmacological management of cancer pain (Part III)
Raghavendra Ramanjulu1, Raghu S Thota2, Arif Ahmed3, Parmanand Jain2, Sushma Bhatnagar4, Naveen Salins5, Aparna Chatterjee2, Dipasri Bhattacharya6
1 Department of Pain and Palliative Care, Cytecare Hospital, Bengaluru, India
2 Department of Anaesthesiology, Critical Care and Pain, Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, Maharashtra, India
3 Department of Anaesthesia, Critical Care and Pain Management, CK Birla Hospital for Women, Gurugram, Haryana, India
4 Department of Onco-anaesthesia and Palliative Medicine, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
5 Department of Palliative Medicine and Supportive Care, Manipal Comprehensive Cancer Care Centre, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India
6 Department of Anaesthesiology, Critical Care and Pain, R.G. Kar Medical College, Kolkata, West Bengal, India
|Date of Submission||15-Oct-2019|
|Date of Decision||02-Dec-2019|
|Date of Acceptance||10-Dec-2019|
|Date of Web Publication||14-Jan-2020|
Dr. Raghu S Thota
Department of Anaesthesiology, Critical Care and Pain, Homi Bhabha National Institute, Tata Memorial Centre, E Borges Road, Parel, Mumbai - 400 012, Maharashtra
Source of Support: None, Conflict of Interest: None
The Indian Society for Study of Pain (ISSP), Cancer Pain Special Interest Group, guidelines on pharmacological management of cancer pain in adults provide a structured, step-wise approach which will help to improve the management of cancer pain and to provide patients with a minimally acceptable quality of life. The guidelines have been developed based on the available literature and evidence, to suit the needs, patient population, and situations in India. A questionnaire based on the key elements of each subdraft addressing certain inconclusive areas where evidence was lacking, was made available on the ISSP website and circulated by E-mail to all the ISSP and Indian Association of Palliative Care members. Antidepressants and/or anticonvulsants should be used to treat neuropathic cancer pain and the dose should be titrated according to the clinical response and side effects. External beam radiotherapy should be offered to all patients with painful metastatic bone pain. There is evidence on the use of ketamine in cancer neuropathic pain, but with no beneficial effect, thus it is not recommended.
Keywords: Bone pain, breakthrough pain, cancer pain management guidelines, cancer pain management, Cancer Pain Special Interest Group, Indian Society for Study of Pain, opioids, WHO analgesic ladder
|How to cite this article:|
Ramanjulu R, Thota RS, Ahmed A, Jain P, Bhatnagar S, Salins N, Chatterjee A, Bhattacharya D. The Indian Society for Study of Pain, Cancer Pain Special Interest Group guidelines on pharmacological management of cancer pain (Part III). Indian J Pain 2019;33, Suppl S1:30-6
|How to cite this URL:|
Ramanjulu R, Thota RS, Ahmed A, Jain P, Bhatnagar S, Salins N, Chatterjee A, Bhattacharya D. The Indian Society for Study of Pain, Cancer Pain Special Interest Group guidelines on pharmacological management of cancer pain (Part III). Indian J Pain [serial online] 2019 [cited 2020 Jan 20];33, Suppl S1:30-6. Available from: http://www.indianjpain.org/text.asp?2019/33/4/30/276065
| Introduction|| |
Although pain is often the primary presenting symptom of cancer and despite the presence of guidelines and the availability of opioids, cancer pain still remains undertreated. Although there are many guidelines available in the literature, they take into account the scope of practice only in the respective countries. Since the patient population is different with respect to the Indian context, they may not work well. Conditions of medical practice are not only different in our country but are also variable, depending on the type of institution/center that one works in. These guidelines are developed to improve the management of cancer pain and to provide the patients with a minimal acceptable quality of life.
| Methods|| |
Literature search [Appendix IV] was carried out using PubMed, MEDLINE, COCHRANE DATABASE, GOOGLE SCHOLAR, and OVID Search engine. The search included studies published in English language until November 2018. Where evidence is lacking, recommendations were made by consensus (good clinical practice), following extensive discussion among the committee members and considering the results of the questionnaire [Appendix V] circulated during the meeting, and also were made available on the Indian Society for Study of Pain (ISSP) website and circulated by E-mail to all the ISSP and Indian Association of Palliative Care (IAPC) members.
| Opioids in Renal and Liver Impairment|| |
Renal impairment (RI) is a common problem encountered in patients with advanced cancer due to age, concomitant illnesses, chemotherapy, or the cancer itself. The metabolites of the opioids are altered as well as accumulated in the presence of RI.,
Morphine is metabolized in the liver to two main metabolites, morphine-3-glucuronide (M3G) (55%) and morphine-6-glucuronide (M6G) (10%), which are excreted renally along with 10% of the parent drug. M6G is a potent analgesic and central nervous system (CNS) depressant. M3G decreases seizure threshold. In patients with renal and/or liver impairment, morphine should be used in lower doses and at longer dosing intervals while SR preparations should be avoided.,
Fentanyl is metabolized in the liver primarily to norfentanyl and other inactive and nontoxic metabolites. In liver disease, the metabolism of fentanyl is affected mainly by decreased hepatic blood flow rather than severe hepatic dysfunction and is therefore relatively safe to be used.,
Tramadol is metabolized in the liver to the active metabolite, O-desmethyltramadol (M1) which contributes to its analgesic effect. Both parent drug and metabolite undergo renal excretion, with approximately 90% of the oral dose excreted by the kidneys, therefore it can accumulate in renal insufficiency. Significant respiratory depression has been reported in patients with severe renal insufficiency, which could be explained by the accumulation of the metabolite M1, which has a high affinity for opioid receptors.
Methadone is primarily excreted in the feces, with approximately 20% excreted unchanged in urine. Methadone tends to accumulate in tissues with chronic use, has a long and variable half-life, and is highly protein bound. There is no clinical evidence for the accumulation of methadone or its metabolites, therefore suggesting that methadone is safe to use in patients with renal disease. It is advised to monitor these patients for signs of opioid toxicity.
Renal clearance of codeine and its metabolite codeine-6-glucuronide is reduced in patients with RI. In addition, codeine is metabolized to morphine and its metabolites that also accumulates in patients with RI. Codeine should be avoided in patients with severe RI.
Buprenorphine is metabolized mainly to norbuprenorphine, which is the only metabolite thought to have analgesic activity with forty times potency less than the original compound. Unchanged buprenorphine is mainly excreted in the feces and its metabolites are mainly excreted in the urine. Buprenorphine is generally safe to use in RI.
| Adjuvant Medications|| |
Adjuvant analgesics are drugs that are not primarily analgesics, but in specific conditions can exhibit analgesic properties. Adjuvant analgesics are prescribed mainly in mixed cancer pain such as neuropathic cancer pain, chemotherapy-induced peripheral neuropathy, and metastatic bone pain (mBP). They are prescribed along with an opioid or by themselves.
| Adjuvant Analgesics for Neuropathic Pain|| |
Antidepressant drugs have been prescribed as an adjuvant for the management of neuropathic pain along with an opioid [Table 1]. Constant vigil should be maintained for serotonin syndrome when used in conjunction with serotinergic medications. They are started at lower doses and increments in dosage are done once in 5–7 days.
Pregabalin and gabapentin are the commonly prescribed adjuvants and act by modulating the function of α2-δ subunit of voltage-gated calcium channels in the dorsal horn of the spinal cord, thus decreasing the release of substance P and glutamate. Pregabalin exhibits an additional anxiolytic activity.
A prospective, randomized, double-blind, placebo-controlled study examined pregabalin versus common neuropathic pain analgesics (gabapentin and amitriptyline) and placebo and concluded that pain scores were statistically significantly lower in the amitriptyline group (P = 0.003) and gabapentin group (P = 0.024). The percentages of patients requiring morphine at the last visit were 56.7% (amitriptyline), 33.3% (gabapentin), 16.7% (pregabalin), and 100% (placebo).
Number needed to treat (NNT) for pregabalin is 7.7, while number needed to treat to harm (NNH) is 13.9.
NNT for gabapentin is 6.3, whereas NNT for gabapentin extended release is 8.3, whereas, NNH is 25.6 and 31.9, respectively.
| Bone Pain|| |
Metastatic bone disease is most commonly seen with specific cancer types, notably those arising from the breast, prostate, lung, and kidney, as well as multiple myeloma. Pain is a debilitating symptom, with skeletal-related events (SRE) leading to loss of mobility and increased dependency that affect their health-related quality of life. Bisphosphonates and RANKL antagonists are bone-specific agents [Table 2],,,,, aimed at relieving bone pain and hypercalcemia and reducing the incidence of SRE. External beam radiotherapy (RT) and radioisotopes also play an important role in the management of mBP.
A single dose of 8 Gy RT gives a profound pain relief in the majority of uncomplicated mBP. RT is the first-line treatment for the majority of patients with metastatic spinal cord compression (mSCC). The ideal dose schedules of 20 Gy in 5 fractions or 8 Gy in two fractions or one fraction are very effective., A single dose of 8 Gy can also be considered for re-irradiation, if there is a recurrence of mBP. In mSCC, steroids should be started immediately, after the diagnosis, with dexamethasone being the commonly used drug. Evidence on loading dose of steroids is limited, but usually doses ranging from moderate (8 mg/day) to ultra-high levels (36–96 mg/day preceded by a bolus of 10–100 mg intravenous) have been advocated in literature and need to be tapered gradually over 2 weeks. Surgery should be advised in patients with spinal instability and recurrence of pain after RT.
Bisphosphonates are the synthetic analogs of pyrophosphates found in the bone matrix, and when administered concentrate primarily at the active remodeling sites. They act by inducing osteoclast apoptosis. RANK ligand antagonist prevents the activation and survival of osteoclasts. When no inflammatory cytokines are released, inflammatory process is dampened, with less stimulation of the highly innervated periosteum, thus reducing pain.,
A Cochrane meta-analysis reviewed thirty randomized controlled studies to determine the effectiveness of bisphosphonates for the relief of pain from bone metastases. NNT was found to be 11 at 4 weeks and 7 at 12 weeks. NNH in terms of adverse effects was 16 at 12 weeks, warranting discontinuation of therapy. Patients who received bisphosphonates had reduced usage of analgesics compared to placebo.
In a systematic review evaluating the analgesic effect of zolendronate and denosumab on bone pain, the quality of evidence of the 43 articles that met the inclusion criteria was very low. Twenty-two (79%) of the 28 placebo-controlled trials found benefit in analgesic property for bisphosphonates. Pain relief was not assessed in the studies on denosumab. Evidence to support the analgesic role of bisphosphonates and denosumab is weak. Bisphosphonates and denosumab are beneficial in preventing pain by delaying the onset of bone pain rather than providing analgesic benefits (denosumab 9.7 vs. 5.8 months for bisphosphonates, P = 0.0024). There was no difference between the two arms, in the time needed to obtain a noticeable decrease in pain intensity once present.
A randomized double-blind study evaluating 1904 men with castration-resistant prostate cancer and bone metastases found denosumab to be better than zoledronic acid for the prevention of SREs. The time to first SRE was 20.7 months with denosumab versus 17.1 months with zoledronic acid (P = 0.0002, hazard ratio 0.82, confidence interval [CI] =0.71–0.95).
Both bisphosphonates and denosumab are generally well tolerated. Zolendronate is associated with episodes of acute-phase response such as transient increase in bone pain, fever, and myalgia, which peak in 24–48 h and resolve within 72 h. Renal dysfunction associated with zolendronate requires regular evaluation of creatinine/creatinine clearance.
Osteonecrosis of the jaw is a complication seen with both therapies. They are associated with a history of tooth extraction, poor oral hygiene, and use of dental appliances. Hypocalcemia is seen more with denosumab. Regular monitoring of calcium levels is needed. Vitamin D and calcium supplementation is strongly advised. In selected group of patients who present with multiple osteoblastic lesions, radioisotopes such as strontium, rhenium, and radium-223 had been extensively studied., A Cochrane meta-analysis reviewed 15 studies to determine the efficacy and safety of radioisotopes in patients with bone metastases and observed a small benefit of radioisotopes for complete relief (risk ratio [RR]: 2.10, 95% CI: 1.32–3.35; NNT to benefit = 5) and complete/partial relief (RR: 1.72, 95% CI: 1.13–2.63; NNT = 4) in the short- and medium term and concluded that radioisotopes provide complete reduction in pain over a period of 1 to 6 months, but severe adverse effects such as leukocytopenia and thrombocytopenia are frequently associated. Except for radium-223, the rest had shown minimal beneficial effects. Radium-223 has been shown to improve SREs and also prolong survival.
| Corticosteroids|| |
Corticosteroids are used as adjuvant analgesics for their anti-inflammatory properties as well as the postulation that this group of medication exerts effect on all the four stages of pain and nociception. Their anti-inflammatory effect is exerted due to the inhibition of inflammatory cytokines and prostaglandin production. The resultant decrease in inflammation leads to decrease in capillary permeability reducing the edema.
Corticosteroids are used in clinical situations of inflammation and edema – in confined spaces including intracranial, spinal, pelvic, or retroperitoneal spaces. They are also used in the relief of pain from space-occupying lesions of brain, spinal cord, nerves, liver, and soft tissues. Dexamethasone is the most studied corticosteroid as it has the least mineralocorticoid activity and due to its long duration of action, can be used once a day.
A randomized, placebo-controlled, double-blind trial, evaluating pain management in adult patients with advanced cancer, concluded that there was no statistically significant relief of pain or reduction in opioid consumption with methylprednisolone versus placebo (P = 0.88 and P = 0.95, respectively). The corticosteroid therapy improved fatigue (P = 0.003), appetite (P = 0.003), and patient well-being (P = 0.001).
Corticosteroids do not improve opioid analgesia or reduce opioid consumption in advanced cancer patients.
A systematic review on the role of corticosteroids in providing analgesia found that moderate doses of corticosteroids equivalent to methylprednisolone 32 mg or dexamethasone 8 mg daily are well tolerated for up to 7 days.
Corticosteroids could make an individual susceptible to adverse effects such as predisposing to infection, hyperglycemia, insulin resistance, proximal myopathy and catabolic effects, skin changes, and adrenal insufficiency. Advanced cancer patients are particularly vulnerable. While prescribing, the risk–benefit balance should be considered.
| Ketamine|| |
N-methyl-d-aspartate (NMDA) receptors are present in the periphery as well as the CNS and are activated when stimulated by the glutamate and aspartate released in response to activated peripheral pain fibers. Acute and chronic stimulation lead to the “wind-up phenomenon” of peripheral pain fibers (A-delta and C) producing symptoms of both allodynia and hyperalgesia, especially in patients with neuropathic pain.
Ketamine is a dissociative anesthetic. The mechanism of action is noncompetitive blockade of the NMDA receptor. The indication for the use of ketamine as an adjuvant in cancer pain management is when pain is unresponsive to opioids or when opioid tolerance occurs. The use of ketamine is restricted due to its adverse effects which include psychomotor retardation and hallucinations.
A recent review of literature from the Cochrane database and from an independent review article, reports the absence of sufficient evidence of benefit of ketamine as an adjuvant in cancer pain., In a randomized controlled trial, analgesic effect was evaluated between ketamine and placebo among cancer patients who had chronic, chemotherapy-induced neuropathic pain. Of the 204 patients randomized, 74.7% were in remission and 97.6% were on medications for neuropathic pain. None were receiving morphine. There was no statistical difference between the two arms for analgesic benefit (P = 0.75). A randomized, double-blind, placebo-controlled study conducted to assess the efficacy of ketamine in patients suffering from cancer pain refractory to opiates did not find benefit of morphine–ketamine combination in refractory pain.
| Anticholinergics and Somatostatin Analog|| |
Malignant bowel obstruction can lead to colicky abdominal pain that can be very debilitating. Anticholinergic drugs reduce the propulsive gut motility and decrease intraluminal secretions, thus reducing the colicky pain.
Octreotide is a somatostatin analog that inhibits the secretion of gastric, pancreatic, and intestinal secretions and reduces gastrointestinal motility.
Researchers in a prospective, randomized clinical trial concluded that all the patients with inoperable malignant bowel obstruction should undergo antisecretory drug treatment and that octreotide should be considered as the first-choice antisecretory drug. Another study concluded that a combination of octreotide with an anticholinergic can be very effective in the symptom management of inoperable bowel obstruction in terminal cancer patients.
| Conclusion|| |
The ISSP cancer pain Special Interest Group (SIG) guidelines for the diagnosis and assessment of cancer pain in adults emphasize the importance of comprehensive pain assessment along with patient education about the availability of various pain control interventions in the form of pharmacological and nonpharmacological methods. It also emphasizes on using unidimensional as well as multidimensional pain scoring tools along with screening of patients for distress and psychological disorders. The most important aspect of these guidelines is recommendation of patient participation and self-reporting of pain [Table 3].
We believe that the ISSP cancer pain SIG guidelines for the diagnosis and assessment of cancer pain in adults will help pain specialists, anesthesiologists, palliative care specialists, and others who are involved in cancer pain care, in the safe management of cancer pain and to provide the patients with a minimally acceptable quality of life.
The ISSP cancer pain SIG guidelines' Guidelines-Developing Committee [Appendix I] would like to thank the members of the ISSP, the IAPC, and other anesthesiologists who responded to the questionnaire and gave their valuable feedback which helped in the formulation of these guidelines.
The ISSP cancer pain SIG would like to wholeheartedly thank the Internal Review Committee [Appendix II] and the external review committee [Appendix III].
The contents of this publication are guidelines to clinical practice, based on the best available evidence at the time of development. These guidelines should neither be construed or serve as a standard of care.
These guidelines do not represent the minimum standard of practice, nor are they a substitution for good clinical judgment. These guidelines need to be used in conjunction with patient assessment and may be individualized as per patient need.
These guidelines were developed in 2018-2019 and may be reviewed again in 2024 or sooner, based on the availability of new evidences.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
Appendix IV: Literature search
The following terms or MeSH terms were used either in combination or single:
“Pain”[Mesh], “Prevalence”[Mesh], “Signs and symptoms”[Mesh], “Syndrome”[Mesh], “Diagnosis”[Mesh], presentation, “Neoplasms”[Mesh], tumors, cancers, physical assessment,” “Pain Measurement”[Mesh], “pain scale,” psychosocial, assessment, “cognitively impaired,” “psychological distress,” distress, “Emotions”[Mesh] “Nursing”[Mesh], “prime assessor,” “Palliative Care”[Mesh], “supportive care,” “cancer pain management,” “Patient-Centered Care”[Mesh], “Patient Care Team”[Mesh], “Patient Care Management”[Mesh], “Primary Health Care” [Mesh], “Physicians, Family”[Mesh], interdisciplinary, Education”[Mesh], outcome, barrier, “World Health Organization”[Mesh], “Guideline “[Publication Type], “cancer pain ladder,” “World Health Organization three step analgesic ladder”[Mesh], Drug Therapy”[Mesh], “Analgesics, Opioid”[Mesh], “administration and dosage”[Subheading], titration, “breakthrough pain,” “Drug Tolerance”[Mesh], “Adjuvants, “adjuvant analgesics,” “pregabalin “[Substance Name], “Ketamine”[Mesh], “Dexamethasone”[Mesh], corticosteroid, “opioid rotation,” “opioid switching,” “alternative opioid,” “Bisphosphonates”[Mesh], “Sedation score,” “Morphine protocol,” “Radiotherapy”[Mesh], “Soft Tissue Neoplasms”[Mesh], “Behavior Therapy”[Mesh], “Cognitive Therapy”[Mesh], “Physical Therapy Modalities”[Mesh], “Acupuncture”[Mesh], “Massage”[Mesh], “Exercise”[Mesh], “Exercise”[Mesh], “Nerve Block, Celiac plexus block, cementoplasty, stellate ganglion block, superior hypogastric plexus block, ganglion impar block”[Mesh], “Injections, Spinal”[Mesh], “intrathecal therapy,” “Vertebroplasty”[Mesh], “follow-up,” “Physician's Role “[Mesh], “community care,” “home program*,” “general practitioner,” hospice, “pain clinic,” “Outpatients”[Mesh], “Outpatient Clinics, Hospital”[Mesh], “Ambulatory Care”[Mesh].
Appendix V: Cancer Pain Management Questionnaire
- How many patients of cancer pain do you manage per month?
- What is the most frequent cancer pain that you encounter in your daily practice?
- What are the clinical presentations of cancer-related pain?
- What are the methods used for the clinical assessment of cancer pain?
- What are the principles of management of pain in patients with cancer?
- What is the WHO analgesic ladder? What are its principles? How effective is it in clinical practice?
- Do you follow WHO step ladder approach for cancer pain management?
- What do you prefer for step II and step III of WHO ladder?
- What nonpharmacological techniques do you use to manage cancer pain
- Do you screen all patients of substance abuse? If yes, which scale do you use?
- What medications do you use to manage cancer pain?
- What are the major side effects you observe due to pharmacological management and how do you manage it?
- What are the adjuvant analgesics in cancer pain management?
- What are the pharmacological strategies for breakthrough pain and other acute pain crises?
- What are the roles of anticancer therapy in the management of cancer pain?
- Do you manage patients using interventional techniques? If yes, which interventional techniques and in what percentage of patients?
- What are the relative efficacy and safety of current invasive treatments for the treatment of cancer-related pain?
- Do you think current treatment guidelines for cancer pain management are sufficient? If no, what changes do you suggest?
- According to you, what steps need to be taken to spread the awareness regarding cancer pain management?
| References|| |
Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 2005;33:311-22.
Johnson SJ. Opioid safety in patients with renal or hepatic dysfunction. Pain treatment topics. 2007;6:1
Douglas C, Murtagh FE, Chambers EJ, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced chronic kidney disease: A review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. Palliat Med 2009;23:103-10.
Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28:497-504.
Scottish Intercollegiate Guidelines Network. Control of Pain in Adults with Cancer. Edinburgh: Scottish Intercollegiate Guidelines Network; 2008.
Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: Recommendations for practice. J Pain Palliat Care Pharmacother 2007;21:5-16.
Ashmore S. Pain control in renal impairment. In: Ashley C, Morlidge C editors. Introduction to renal therapeutics. London, Pharmaceutical Press: 2008.p.191-204.
Watson M, Lucas C, Hoy A, Back I, Armstrong P, editors. Palliative Adult Network Guidelines (PANG). 3rd ed. Nine Cancer Networks across the UK; 2011.
Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980;5:197-205.
Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004;5:2-19.
Launay-Vacher V, Karie S, Fau JB, Izzedine H, Deray G. Treatment of pain in patients with renal insufficiency: The World Health Organization three-step ladder adapted. J Pain 2005;6:137-48.
Böger RH. Renal impairment: A challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006;20 Suppl 1:s17-23.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al
. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: A prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 2012;29:177-82.
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: A population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 2011;129:495-503.
Milner RJ, Farese J, Henry CJ, Selting K, Fan TM, de Lorimier LP. Bisphosphonates and cancer. J Vet Intern Med 2004;18:597-604.
Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al
. Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965-76.
Maranzano E, Bellavita R, Rossi R, De Angelis V, Frattegiani A, Bagnoli R, et al
. Short-course versus split-course radiotherapy in metastatic spinal cord compression: Results of a phase III, randomized, multicenter trial. J Clin Oncol 2005;23:3358-65.
Rades D, Šegedin B, Conde-Moreno AJ, Garcia R, Perpar A, Metz M, et al
. Radiotherapy with 4 Gy×5 Versus 3 Gy×10 for metastatic epidural spinal cord compression: Final results of the SCORE-2 trial (ARO 2009/01). J Clin Oncol 2016;34:597-602.
Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, et al
. Single versus multiple fractions of repeat radiation for painful bone metastases: A randomised, controlled, non-inferiority trial. Lancet Oncol 2014;15:164-71.
Loblaw DA, Mitera G, Ford M, Laperriere NJ. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys 2012;84:312-7.
Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al
. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018;29:iv166-91.
Middlemiss T, Laird BJ, Fallon MT. Mechanisms of cancer-induced bone pain. Clin Oncol (R Coll Radiol) 2011;23:387-92.
Coleman R. The use of bisphosphonates in cancer treatment. Ann N
Y Acad Sci 2011;1218:3-14.
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al
. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al
. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al
. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132-9.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al
. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al
. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21.
Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, et al
. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): Secondary outcomes from a randomised controlled trial. Lancet Oncol 2011;12:743-52.
Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002;2:CD002068.
Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project. Palliat Med 2017;31:5-25.
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al
. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813-22.
Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2014;25 Suppl 3:iii124-37.
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al
. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008;19:420-32.
Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. WITHDRAWN: Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2017;3:CD003347.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al
. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15:738-46.
Pharo GH, Zhou L. Pharmacologic management of cancer pain. J Am Osteopath Assoc 2005;105:S21-8.
Haywood A, Good P, Khan S, Leupp A, JenkinsMarsh S, Rickett K, et al
. Corticosteroids for the management of cancerrelated pain in adults. Cochrane Database Syst Rev 2015;4:CD010756.
Paulsen O, Klepstad P, Rosland JH, Aass N, Albert E, Fayers P, et al
. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: A randomized, placebo-controlled, double-blind trial. J Clin Oncol 2014;32:3221-8.
Mercadante SL, Berchovich M, Casuccio A, Fulfaro F, Mangione S. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007;24:13-9.
Paulsen Ø, Aass N, Kaasa S, Dale O. Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manage 2013;46:96-105.
Hatano Y, Matsuoka H, Lam L, Currow DC. Side effects of corticosteroids in patients with advanced cancer: A systematic review. Support Care Cancer 2018;26:3979-83.
Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: A review. Anesth Analg 2003;97:1108-16.
Hocking G, Cousins MJ. Ketamine in chronic pain management: An evidence-based review. Anesth Analg 2003;97:1730-9.
Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: What is the evidence? Curr Opin Support Palliat Care 2017;11:88-92.
Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2017;6:CD003351.
Fallon MT, Wilcock A, Kelly CA, Paul J, Lewsley LA, Norrie J, et al
. Oral Ketamine vs. placebo in patients with cancer-related neuropathic pain: A randomized clinical trial. JAMA Oncol 2018;4:870-2.
Salas S, Frasca M, Planchet-Barraud B, Burucoa B, Pascal M, Lapiana JM, et al
. Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: Considerations about the clinical research in palliative care. J Palliat Med 2012;15:287-93.
Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L. Comparison of octreotide administration vs. conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: A randomized, double- blind, controlled clinical trial. Anticancer Res 2002;22:1187-92.
Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial. J Pain Symptom Manage 2000;19:23-34.
[Table 1], [Table 2], [Table 3]